BioDlink Biopharm Co., Ltd.
Quick facts
Phase 3 pipeline
- TAB008 · Diabetes
TAB008 is a small molecule that targets the SGLT2 receptor. - TAB014 Monoclonal Antibody Injection
TAB014 is a monoclonal antibody that targets an unspecified molecular target to treat various conditions.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: